The Utility of Steady State Trough Concentrations in Assessing Intrasubject Variability

Abstract

During drug development, trough concentrations are usually monitored following repeated dosing to ensure that steady state has been achieved. Further utility of this information is explored in the estimation of intrasubject variability. Intrasubject variability is essential to the determination of sample sizes for planning within-subject (ie, crossover) studies of the effects of meals, concomitant drugs, or formulation changes (ie, bioequivalence). The utility of steady state trough concentration was evaluated as an indicator of intrasubject variability compared to a conventional approach of using a fraction of intersubject variability and to estimates obtained directly from crossover studies. Based on available data, estimates of intrasubject variability by the trough concentration approach were comparable to those from the other two approaches.

Keywords

Intrasubject variability Trough concentration Steady state

Get full access to this article

View all access options for this article.

References

Lobo

Jack

Kendall

. The Intrasubject and Intersubject Variability of Nifedipine Pharmacokinetics in Young Volunteers. Eur J Clin Pharm. 1986; 30:57–60.

Jaffe

Schran

. Clinical Pharmacokinetics in Drug Discovery and Development. In: Welling

Tse

FLS

ed. Pharmacokinetics, Regulatory, Industrial, Academic Perspectives. New York: Dekker, Inc.; 1988:215–266.

Pierce

Abrams

SML

Franklin

. Intra-subject and Inter-subject Variation in the Pharmacokinetics of Indoramin and Its 6-hydroxylated Metabolite. Eur J Clin Pharmacol. 1988;35:195–198.

Kochak

Smith

Choi

. Intra- and Intersubject Variability: Mixed-Effects Statistical Analysis of Repeated Doses of An Angiotensin Converting Enzyme Inhibitor, CGS 16617. Pharma Res. 1989;6(4):328–331.

Awni

Skaar

Schwenk

. Interindividual and Intraindividual Variability in Labetalol Pharmacokinetics. J Clin Pharmcol. 1988;28:344–349.

Joshi

King

S-YP

Pieniaszek

. Interand Intra-subject Variability in the Pharmacokinetics of Low Dose Acetylsalicylic Acid (ASA) in Healthy Volunteers. Pharma Res. 1994;11(10 suppl):S446.

Cabana

. Assessment of 75/75 Rule: FDA Viewpoint. J Pharm Sci. 1983;72:98–99.

Liu

. Use of the Repeated Cross-over Designs in Assessing Bioequivalence. Stat Med. 1995;14:1067–1078.

Walker

Mosqueda

. A Simple Test to Evaluate Effect of Product Variation by Intra-subject Variation. Pharma Res. 1995;12(9 Suppl):S397.

10.

Walker

Mosqueda

. The Effect of Product Variation on Intra-subject Variability in Bioequivalence Studies. Pharma Res. 1995; 12(9 suppl): S423.

11.

Huebner

Eismann

Koall

. Comparison of Intra-patient Trough Blood Levels of Ciclosporin after Oral Application of Sandimmun® or Sandimmum® Optoral. Eur J Clin Pharmacol. 1995;49(1–2):A154.

12.

Kahan

Dunn

Fitts

. Reduced Interand Intrasubject Variability in Cyclosporine Pharmacokinetics in Renal Transplant Recipients Treated with A Microemulsion Formulation in Conjunction with Fasting, Low-fat Meals, or High-fat Meals. Transplant. 1995;59(4):505–511.

13.

Rowland

Tozer

. Clinical Pharmacokinetics: Concepts and Applications. Third Edition. Media, PA: Williams & Wilkins; 1995;469–472.

14.

Schuirmann

. A Comparison of the Two Onesided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability. J Pharmacokin Biopharm. 1987;15:657–680.

15.

Diletti

Hauschke

Steinijans

. Sample Size Determination for Bioequivalence Assessment by Means of Confidence Intervals. Int J Clin Pharmacol Ther Toxicol. 1991;29:1–8.

16.

SAS Institute Inc. SAS/STAT® User's Guide, Version 6. Fourth Edition, Volume 2. Cary, NC: SAS Institute Inc.; 1990.

17.

SAS Institute Inc. SAS Technical Report P-229. SAS/STAT® Software: Changes and Enhancements, Release 6.07. Cary, NC: SAS Institute Inc.; 1992:287–366.

18.

Food and Drug Administration, Office of Generic Drugs, Division of Bioequivalence. Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Rockville, MD: Food and Drug Administration; 1992.